SEARCH

SEARCH BY CITATION

References

  • Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA & Malik EM (2010) Dihydroartemisinin–piperaquine versus artemether–lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Annals of Tropical Medicine and Parasitology 104, 319326.
  • Anderson TJ, Nair S, Nkhoma S et al. (2010) High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in Western Cambodia. Journal of Infectious Diseases 201, 13261330.
  • Ashley EA, McGready R, Hutagalung R et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clinical Infectious Diseases 41, 425432.
  • Awab GR, Pukrittayakamee S, Imwong M et al. (2010) Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malaria J 9, 105.
  • Basco LK & Ringwald P (2003) In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrobial Agents and Chemotherapy 47, 13911394.
  • Bassat Q, Mulenga M, Tinto H et al. (2009) Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a Randomised, non-inferiority trial. PLoS ONE 4, e7871.
  • Briolant S, Henry M, Oeuvray C et al. (2010) Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp and pfnhe genes in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 54, 35373544.
  • Davis TM (2005) Piperaquine: a resurgent antimalarial drug. Drugs 65, 7587.
  • Deloron P, Le Bras J, Ramanamirija JA & Coulanges P (1985) Plasmodium falciparum in Madagascar: in vivo and in vitro sensitivity to seven drugs. Annals of Tropical Medicine and Parasitology 79, 357365.
  • Denis MB, Davis TM, Hewitt S et al. (2002) Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clinical Infectious Diseases 35, 14691476.
  • Dondorp AM, Nosten F, Yi P et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine 361, 455467.
  • Grande T, Bernasconi A, Erhart A et al. (2007) A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS ONE 2, e1101.
  • Hasugian AR, Purba HL, Kenangalem E et al. (2007) Dihydroartemisinin–piperaquine versus artesunate–amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases 44, 10671074.
  • Imwong M, Dondorp AM, Nosten F et al. (2010) Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 54, 28862892.
  • Janssens B, van Herp M, Goubert L et al. (2007) A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health 12, 251259.
  • Kamya MR, Yeka A, Bukirwa H et al. (2007) Artemether–lumefantrine versus dihydroartemisinin–piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2, e20.
  • Karema C, Fanello CI, van Overmeir C et al. (2006) Safety and efficacy of dihydroartemisinin/piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene 100, 11051111.
  • Karunajeewa HA, Mueller I, Senn M et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 359, 25452557.
  • Legros D, Johnson K, Houpikian P et al. (2002) Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, 199201.
  • Mehlotra RK, Fujioka H, Roepe PD et al. (2001) Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proceedings of the National Academy of Sciences of the United States of America 98, 1268912694.
  • Mu J, Myers RA, Jiang H et al. (2010) Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet 42, 260272.
  • Muangnoicharoen S, Johnson DJ, Looareesuwan S, Krudsood S & Ward SA (2009) Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrobial Agents and Chemotherapy 53, 13621366.
  • Mwai L, Kiara SM, Abdirahman A et al. (2009) In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrobial Agents and Chemotherapy 53, 50695073.
  • Myint HY, Ashley EA, Day NP, Nosten F & White NJ (2007) Efficacy and safety of dihydroartemisinin-piperaquine. Transactions of the Royal Society of Tropical Medicine and Hygiene 101, 858866.
  • Noedl H, Se Y, Schaecher K, Smith BL, Socheat D & Fukuda MM (2008) Evidence of artemisinin-resistant malaria in Western Cambodia. New England Journal of Medicine 359, 26192620.
  • Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B & Rosenthal PJ (2010) In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrobial Agents and Chemotherapy 54, 12001206.
  • Price RN, Dorsey G & Nosten F (2009) Antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 360, 1254.
  • Ratcliff A, Siswantoro H, Kenangalem E et al. (2007) Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369, 757765.
  • Raynes K (1999) Bisquinoline antimalarials: their role in malaria chemotherapy. International Journal for Parasitology 29, 367379.
  • Russell B, Chalfein F, Prasetyorini B et al. (2008) Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrobial Agents and Chemotherapy 52, 10401045.
  • Sá JM, Twu O, Hayton K et al. (2009) Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proceedings of the National Academy of Sciences of the United States of America 106, 1888318889.
  • Sidhu AB, Verdier-Pinard D & Fidock DA (2002) Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210213.
  • Sinclair D, Zani B, Donegan S, Olliaro P & Garner P (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 3, CD007483.
  • Smithuis F, Kyaw MK, Phe O et al. (2006) Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367, 20752085.
  • Somé AF, Séré YY, Dokomajilar C et al. (2010) Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine/sulfadoxine-pyrimethamine, but not by dihydroartemisinin-piperaquine in Burkina Faso. Antimicrobial Agents and Chemotherapy 54, 19491954.
  • Thanh NX, Trung TN, Phong NC et al. (2009) Open label randomized comparison of dihydroartemisinin–piperaquine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Tropical Medicine and International Health 14, 504511.
  • Tip NQ, Trung TN, Tan TV & Phuc NT (2001) A field trial for efficacy of CV8 in treatment of uncomplicated falciparum malaria. J Malaria Parasit Dis Cont 4, 4551.
  • Tran TH, Dolecek C, Pham PM et al. (2004) Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: a randomised clinical trial. Lancet 363, 1224.
  • Valecha N, Phyo AP, Mayxay M et al. (2010) An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS ONE 5, e11880.
  • Whegang SY, Tahar R, Foumane VN et al. (2010) Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malaria J 9, 56.
  • Witkowski B, Lelièvre J, Barragán MJ et al. (2010) Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrobial Agents and Chemotherapy 54, 18721877.
  • World Health Organization (2010) Guidelines for the treatment of malaria, 2nd edn. Geneva, Switzerland.( http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html ).
  • Yeka A, Dorsey G, Kamya MR et al. (2008) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE 3, e2390.
  • Zongo I, Dorsey G, Rouamba N et al. (2007) Randomized comparison of amodiaquine plus sulfadoxine–pyrimethamine, artemether–lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clinical Infectious Diseases 45, 14531461.